Macular Degeneration Trial, Recruiting NCT02253030 Sponsor: Oregon Health and Science University Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT02253030
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with wet AMD (age-related macular degeneration):

  • Adults aged 50 or older who have been diagnosed with wet AMD with active abnormal blood vessel growth, and who have never received treatment for it before

For people with healthy eyes (comparison group):

  • People who show no signs of retinal disease
  • People whose glasses or contact lens prescription is not stronger than +3.00 or weaker than -7.00 diopters (confirm with trial site)
  • People who have not had any eye surgery in the last 4 months
  • People who do not have a significant cataract that could affect the quality of eye scan images

Who may not be able to join:

  • People who are unable to give their informed consent to take part in the trial
  • People who have significant kidney disease
  • People whose blood pressure is higher than 180/110
  • People who have previously had laser treatment on the central part of their retina (macula)
  • People who have difficulty keeping their gaze steady during eye scanning (OCT imaging)
  • People whose vision is worse than 20/200, even with glasses or contact lenses

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Steven Bailey, MD, Oregon Health and Science University

Phone: 503-494-7398

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2014
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Measure of choroidal neovascular (CNV) vessel area in mm2; Measure of CNV membrane area in mm2; Measure of CNV length density in mm; Measure of retinal fluid volume in mm3; Measure of drusen area in mm2

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov